[1]王心如,海鑫,李文兰.ATO对肿瘤微环境中免疫细胞的调节作用研究进展[J].陕西医学杂志,2026,(8):1148-1152.[doi:DOI:10.3969/j.issn.1000-7377.2026.08.023]
　WANG Xinru,HAI Xin,LI Wenlan.Research progress on regulatory effects of ATO on immune cells in tumor microenvironment[J].,2026,(8):1148-1152.[doi:DOI:10.3969/j.issn.1000-7377.2026.08.023]
点击复制

ATO对肿瘤微环境中免疫细胞的调节作用研究进展

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年8期
页码:
1148-1152
栏目:
综述
出版日期:
2026-08-05

文章信息/Info

Title:
Research progress on regulatory effects of ATO on immune cells in tumor microenvironment
作者:
王心如1; 海鑫2; 李文兰1
（1.哈尔滨商业大学药学院，黑龙江 哈尔滨 150076；2.哈尔滨医科大学附属第一医院，黑龙江 哈尔滨 150001）
Author(s):
WANG Xinru1; HAI Xin2; LI Wenlan1
（1.School of Pharmacy,Harbin University of Commerce,Harbin 150076,China;2.The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)
关键词:
三氧化二砷; 肿瘤微环境; 免疫调控; 肿瘤转移; 免疫检查点抑制剂; 免疫细胞
Keywords:
Arsenic trioxide; Tumor microenvironment; Immune regulation; Tumor metastasis; Immune checkpoint inhibitors; Immune cells
分类号:
R 285
DOI:
DOI:10.3969/j.issn.1000-7377.2026.08.023
文献标志码:
A
摘要:
三氧化二砷（ATO）在急性早幼粒细胞白血病（APL）治疗中已取得显著成效，近年来研究发现其在调节肿瘤微环境（TME）免疫细胞功能、抑制肿瘤转移方面亦展现出巨大潜力。现对ATO通过调控TME中巨噬细胞、T淋巴细胞、自然杀伤（NK）细胞及髓源性抑制细胞（MDSCs）等功能，逆转免疫抑制状态，进而抑制肿瘤转移的分子机制进行综述。同时，探讨ATO与免疫检查点抑制剂（ICIs）的协同作用，以期为拓展ATO的临床应用及开发新型抗肿瘤策略提供理论依据。
Abstract:
Arsenic trioxide (ATO) has achieved remarkable efficacy in the treatment of acute promyelocytic leukemia (APL).Recent studies have found that it also exhibits great potential in regulating the functions of immune cells in tumor microenvironment (TME) and inhibiting tumor metastasis.This article reviews the molecular mechanisms by which ATO reverses immunosuppressive state and further inhibits tumor metastasis via regulating the functions of macrophages,T lymphocytes,natural killer (NK) cells,myeloid-derived suppressor cells (MDSCs) and other immune cells in TME.Meanwhile,the synergistic effect between ATO and immune checkpoint inhibitors (ICIs) is discussed,so as to provide theoretical basis for expanding the clinical application of ATO and developing novel anti-tumor strategies.

参考文献/References:

[1]XIAO Y,YU D.Tumor microenvironment as a therapeutic target in cancer[J].Pharmacol Ther,2021,221:107753.
[2]ARNETH B.Tumor microenvironment[J].Medicina,2019,56(1):15.
[3]GIRALDO N A,SANCHEZ-SALAS R,PESKE J D,et al.The clinical role of the TME in solid cancer[J].Br J Cancer,2019,120(1):45-53.
[4]LI H,FAN X,HOUGHTON J M.Tumor microenvironment:The role of the tumor stroma in cancer[J].J Cell Biochem,2007,101(4):805-815.
[5]EBLE J A,NILAND S.The extracellular matrix in tumor progression and metastasis[J].Clin Exp Metastasis,2019,36(3):171-198.
[6]FULLAR A,DUDAS J,OLAH L,et al.Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression[J].BMC Cancer,2015,15(1):256.
[7]ARAS S,ZAIDI M R.TAMeless traitors:Macrophages in cancer progression and metastasis[J].Br J Cancer,2017,117(11):1583-1591.
[8]TALMADGE J E,GABRILOVICH D I.History of myeloid-derived suppressor cells[J].Nat Rev Cancer,2013,13(10):739-752.
[9]OHUE Y,NISHIKAWA H.Regulatory T (Treg) cells in cancer:Can Treg cells be a new therapeutic target?[J].Cancer Sci,2019,110(7):2080-2089.
[10]YIN X,CHEN S,EISENBARTH S C.Dendritic cell regulation of T helper cells[J].Annu Rev Immunol,2021,39(1):759-790.
[11]WU S Y,FU T,JIANG Y Z,et al.Natural killer cells in cancer biology and therapy[J].Mol Cancer,2020,19(1):120.
[12]YILMAZ M,KANTARJIAN H,RAVANDI F.Acute promyelocytic leukemia current treatment algorithms[J].Blood Cancer J,2021,11(6):123.
[13]IYER S G,ELIAS L,STANCHINA M,et al.The treatment of acute promyelocytic leukemia in 2023:Paradigm,advances,and future directions[J].Front Oncol,2023,12:1062524.
[14]MUNSHI N C,TRICOT G,DESIKAN R,et al.Clinical activity of arsenic trioxide for the treatment of multiple myeloma[J].Leukemia,2002,16(9):1835-1837.
[15]YANG M H,WANG Y S,SHI X Q,et al.Arsenic trioxide restrains lung cancer growth and metastasis by blocking the calcineurin-NFAT pathway by upregulating DSCR1[J].Curr Cancer Drug Targets,2022,22(10):854-864.
[16]李欣,潘宇飞,万旭英.三氧化二砷在肿瘤治疗中临床应用及相关分子机制研究进展[J].陕西医学杂志,2024,53(5):703-706.
[17]YIN J Z,SHI X Q,WANG M D,et al.Arsenic trioxide elicits anti-tumor activity by inhibiting polarization of M2-like tumor-associated macrophages via Notch signaling pathway in lung adenocarcinoma[J].Int Immunopharmacol,2023,117:109899.
[18]GAO J,LIANG Y,WANG L.Shaping polarization of tumor-associated macrophages in cancer immunotherapy[J].Front Immunol,2022,13:888713.
[19]LI M,YANG Y,XIONG L,et al.Metabolism,metabolites,and macrophages in cancer[J].J Hematol Oncol,2023,16(1):80.
[20]YUNNA C,MENGRU H,LEI W,et al.Macrophage M1/M2 polarization[J].Eur J Pharmacol,2020,877:173090.
[21]ZENG W,LI F,JIN S,et al.Functional polarization of tumor-associated macrophages dictated by metabolic reprogramming[J].J Exp Clin Cancer Res,2023,42(1):245.
[22]XU G,GUO J,FAN S,et al.Single-cell omics analysis reveals tumor microenvironment rewiring after arsenic trioxide therapy in acute promyelocytic leukemia[J].Sci Bull (Beijing),2026,71(4):722-726.
[23]JIANG L,WANG X,RAZA F,et al.PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy[J].Biomater Sci,2023,11(15):5301-5319.
[24]QIU Y,WU Z,CHEN Y,et al.Nano ultrasound contrast agent for synergistic chemo-photothermal therapy and enhanced immunotherapy against liver cancer and metastasis[J].Adv Sci (Weinh),2023,10(21):2300878.
[25]LIU X,SU Y,SUN X,et al.Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization[J].Sci China Life Sci,2020,63(11):1744-1754.
[26]JIANG T,HUANG J B,XU C Y,et al.Arsenic trioxide cooperate cryptotanshinone exerts antitumor effect by medicating macrophage polarization through glycolysis[J].J Immunol Res,2022,2022:2619781.
[27]ASHBY K M,HOGQUIST K A.A guide to thymic selection of T cells[J].Nat Rev Immunol,2024,24(2):103-117.
[28]CHOPP L,REDMOND C,O’SHEA J J,et al.From thymus to tissues and tumors:A review of T-cell biology[J].J Allergy Clin Immunol,2023,151(1):81-97.
[29]SPARTZ M,KIRCHNER K,BLOHM S,et al.CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes[J].Cancer Res,2010,70(21):8368-8377.
[30]KEPP O,PAN H,LIU P,et al.Arsenic trioxide as an inducer of immunogenic cell death[J].Oncoimmunology,2023,12(1):2174723.
[31]ZHAO J,SONG Y,LIU L,et al.Effect of arsenic trioxide on the Tregs ratio and the levels of IFN-γ,IL-4,IL-17 and TGF-β1 in the peripheral blood of severe aplastic anemia patients[J].Medicine (Baltimore),2020,99(26):e20630.
[32]GERA R,SINGH V,MITRA S,et al.Arsenic exposure impels CD4 commitment in thymus and suppress T cell cytokine secretion by increasing regulatory T cells[J].Sci Rep,2017,7(1):7140.
[33]AN K,XUE M J,ZHONG J Y,et al.Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice by inducing CD4+ T cell apoptosis[J].J Neuroinflammation,2020,17(1):147.
[34]MYERS J A,MILLER J S.Exploring the NK cell platform for cancer immunotherapy[J].Nat Rev Clin Oncol,2021,18(2):85-100.
[35]LENART M,RUTKOWSKAZAPAA M,SIEDLAR M.NK-cell receptor modulation in viral infections[J].Clin Exp Immunol,2024,217(2):151-158.
[36]JIA H,YANG H,XIONG H,et al.NK cell exhaustion in the tumor microenvironment[J].Front Immunol,2023,14:1303605.
[37]PIETRA G,MANZINI C,RIVARA S,et al.Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity[J].Cancer Res,2012,72(6):1407-1415.
[38]LEE J C,LEE K M,KIM D W,et al.Elevated TGF-β1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients[J].J Immunol,2004,172(12):7335-7340.
[39]WILSON E B,ELJAWHARI J J,NEILSON A L,et al.Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity[J].PLoS One,2011,6(9):e22842.
[40]ALEX A A,GANESAN S,PALANI H K,et al.Arsenic trioxide enhances the NK cell cytotoxicity against acute promyelocytic leukemia while simultaneously inhibiting its bio-genesis[J].Front Immunol,2018,9:1357.
[41]GONZALEZ S,LOPEZSOTO A,SUAREZALVAREZ B,et al.NKG2D ligands:Key targets of the immune response[J].Trends Immunol,2008,29(8):397-403.
[42]KIM J Y,BAE J H,LEE S H,et al.Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide[J].J Immunother,2008,31(5):475-486.
[43]ZHANG M,CHEN S,CUI Y,et al.Curcumin combined with arsenic trioxide enhances autophagy and immune surveillance to inhibit immune escape in acute myeloid leukemia[J].Int Immunopharmacol,2025,159:114966.
[44]MUENST S,LAUBLI H,SOYSAL S D,et al.The immune system and cancer evasion strategies:Therapeutic concepts[J].J Intern Med,2016,279(6):541-562.
[45]DIAZMONTERO C M,FINKE J,MONTERO A J.Myeloid-derived suppressor cells in cancer:Therapeutic,predictive,and prognostic implications[J].Semin Oncol,2014,41(2):174-184.
[46]SUI H,DONGYE S,LIU X,et al.Immunotherapy of targeting MDSCs in tumor microenvironment[J].Front Immunol,2022,13:990463.
[47]BRONTE V,BRANDAU S,CHEN S H,et al.Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards[J].Nat Commun,2016,7:12150.
[48]GAO Q,JIANG J,CHU Z,et al.Arsenic trioxide inhibits tumor-induced myeloid-derived suppressor cells and enhances T-cell activity[J].Oncol Lett,2017,13(4):2141-2150.
[49]LIU J,ZHANG X,CHENG Y,et al.Dendritic cell migration in inflammation and immunity[J].Cell Mol Immunol,2021,18(11):2461-2471.
[50]SITTIG S P,DE VRIES I J M,SCHREIBELT G.Primary human blood dendritic cells for cancer immunotherapy-tailoring the immune response by dendritic cell maturation[J].Biomedicines,2015,3(4):282-303.
[51]GUPTA Y H,KHANOM A,ACTON S E.Control of dendritic cell function within the tumour microenvironment[J].Front Immunol,2022,13:733800.
[52]YE Y,RICARD L,SIBLANY L,et al.Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon-α inhibition[J].Acta Pharm Sin B,2020,10(6):1061-1072.
[53]WANG X,CHENG S,XU Y,et al.Arsenic trioxide enhances the efficacy of PD-1 inhibitors in hepatocellular carcinoma by inducing immunogenic cell death via the ROS/ERS pathway[J].Immun Inflamm Dis,2025,13(6):e70214.
[54]BRADY M T,MILLER A,SAIT S N,et al.Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function[J].Leuk Res,2013,37(7):822-828.
[55]DEJAS L,SANTONI K,MEUNIER E,et al.Regulated cell death in neutrophils:From apoptosis to NETosis and pyroptosis[J].Semin Immunol,2023,70:101849.
[56]NEMETH T,SPERANDIO M,MCSAY A.Neutrophils as emerging therapeutic targets[J].Nat Rev Drug Discov,2020,19(4):253-275.
[57]YAN M,ZHENG M,NIU R,et al.Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications[J].Front Cell Dev Biol,2022,10:938289.
[58]BINET F,CHIASSON S,GIRARD D.Interaction between arsenic trioxide (ATO) and human neutrophils[J].Hum Exp Toxicol,2011,30(5):416-424.
[59]BINET F,CAVALLI H,MOISAN E,et al.Arsenic trioxide (AT) is a novel human neutrophil pro-apoptotic agent:Effects of catalase on AT-induced apoptosis,degradation of cytoskeletal proteins and de novo protein synthesis[J].Br J Haematol,2006,132(3):349-358.
[60]BINET F,CHIASSON S,GIRARD D.Arsenic trioxide induces de novo protein synthesis of annexin-1 in neutrophils:Association with a heat shock-like response and not apoptosis[J].Br J Haematol,2008,140(4):454-463.
[61]XIA L,LIU Y,WANG Y.PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer:Current status and future directions[J].Oncologist,2019,24(S1):S31-S41.
[62]LI X,PAN Y F,CHEN Y B,et al.Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma[J].Cell Death Dis,2024,15(4):300.
[63]ZHAO Y,LI Y,ZOU J,et al.Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer[J].Br J Cancer,2024,131(12):1928-1941.
[64]ZHU G,LI X,LI J,et al.Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma[J].J Cancer,2020,11(22):6516.

相似文献/References:

[1]陈正浤,雷光焰△,韩 乐,等.三氧化二砷抑制人肺癌细胞NCI-H460增殖并促进其凋亡实验研究*[J].陕西医学杂志,2020,49(10):1219.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.005]
[2]李 欣,潘宇飞,万旭英.三氧化二砷在肿瘤治疗中临床应用及相关分子机制研究进展[J].陕西医学杂志,2024,(5):703.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.029]
　LI Xin,PAN Yufei,WAN Xuying.Research progress on clinical application and related molecular mechanism of arsenic trioxide in tumor treatment[J].,2024,(8):703.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.029]
[3]单莉平,刘倩,宋琼,等.放射治疗与肿瘤疫苗联合在肿瘤治疗中的应用研究进展[J].陕西医学杂志,2025,54(8):1141.[doi:DOI:10.3969/j.issn.1000-7377.2025.08.026]
　SHAN Liping,LIU Qian,SONG Qiong,et al.Research progress on the application of radiotherapy combined with tumor vaccines in cancer treatment[J].,2025,54(8):1141.[doi:DOI:10.3969/j.issn.1000-7377.2025.08.026]
[4]周倩,张欣雨,隋美娟.全反式维甲酸和三氧化二砷诱导治疗初发急性早幼粒细胞白血病患者肝损害风险分析[J].陕西医学杂志,2026,(7):952.[doi:DOI:10.3969/j.issn.1000-7377.2026.07.014]
　ZHOU Qian,ZHANG Xinyu,SUI Meijuan.Risk analysis of hepatotoxicity induced by all-Trans retinoic acid and arsenic trioxidein the treatment of newly diagnosed acute promyelocytic leukemia patients[J].,2026,(8):952.[doi:DOI:10.3969/j.issn.1000-7377.2026.07.014]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82274028）
更新日期/Last Update: 2026-08-13